217 related articles for article (PubMed ID: 17948364)
21. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
Hollander P
Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
[TBL] [Abstract][Full Text] [Related]
22. Role of the endocannabinoid system in energy balance regulation and obesity.
Cota D
Front Horm Res; 2008; 36():135-145. PubMed ID: 18230900
[TBL] [Abstract][Full Text] [Related]
23. Modification of cardiometabolic risk through cannabinoid type-1 receptor antagonism.
Andrikopoulos GK; Tzeis S
Angiology; 2008; 59(2 Suppl):44S-8S. PubMed ID: 18635590
[TBL] [Abstract][Full Text] [Related]
24. Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors.
Cox SL
Drugs Today (Barc); 2005 Aug; 41(8):499-508. PubMed ID: 16234873
[TBL] [Abstract][Full Text] [Related]
25. The endocannabinoid system and the control of glucose homeostasis.
Nogueiras R; Rohner-Jeanrenaud F; Woods SC; Tschöp MH
J Neuroendocrinol; 2008 May; 20 Suppl 1():147-51. PubMed ID: 18426514
[TBL] [Abstract][Full Text] [Related]
26. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
Ducobu J; Sternon J
J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
[TBL] [Abstract][Full Text] [Related]
27. What is the potential role of cannabinoid-1 receptor blockade in glucose and lipid management?
Jensen MD
Am J Med; 2007 Sep; 120(9 Suppl 1):S25-31; discussion S31-2. PubMed ID: 17720358
[TBL] [Abstract][Full Text] [Related]
28. The endocannabinoid system and cardiometabolic risk: effects of CB1 receptor blockade on lipid metabolism.
Deedwania P
Int J Cardiol; 2009 Jan; 131(3):305-12. PubMed ID: 18715660
[TBL] [Abstract][Full Text] [Related]
29. [Blocking the endocannabinoid system -- weight reduction and cardiovascular risk management].
Bramlage P; Böcking W; Kirch W
Dtsch Med Wochenschr; 2005 Mar; 130(12):665-8. PubMed ID: 15776349
[TBL] [Abstract][Full Text] [Related]
30. Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders.
Scheen AJ; Paquot N
Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):103-16. PubMed ID: 19285264
[TBL] [Abstract][Full Text] [Related]
31. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors.
Gelfand EV; Cannon CP
Expert Opin Investig Drugs; 2006 Mar; 15(3):307-15. PubMed ID: 16503766
[TBL] [Abstract][Full Text] [Related]
32. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.
Christopoulou FD; Kiortsis DN
J Clin Pharm Ther; 2011 Feb; 36(1):10-8. PubMed ID: 21198716
[TBL] [Abstract][Full Text] [Related]
33. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.
Silvestri C; Di Marzo V
Expert Opin Investig Drugs; 2012 Sep; 21(9):1309-22. PubMed ID: 22780328
[TBL] [Abstract][Full Text] [Related]
34. [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].
Scheen AJ; Van Gaal LG; Després JP; Pi-Sunyer X; Golay A; Hanotin C
Rev Med Suisse; 2006 Aug; 2(76):1916-23. PubMed ID: 16972542
[TBL] [Abstract][Full Text] [Related]
35. [Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes].
Scheen AJ; Van Gaal LF
Rev Med Liege; 2007 Feb; 62(2):81-5. PubMed ID: 17461296
[TBL] [Abstract][Full Text] [Related]
36. Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk.
Mach F; Montecucco F; Steffens S
Pharmacol Rep; 2009; 61(1):13-21. PubMed ID: 19307689
[TBL] [Abstract][Full Text] [Related]
37. Role of the endocannabinoid system in management of patients with type 2 diabetes mellitus and cardiovascular risk factors.
Davis SN; Perkins JM
Endocr Pract; 2007; 13(7):790-804. PubMed ID: 18194939
[TBL] [Abstract][Full Text] [Related]
38. Rimonabant.
Henness S; Robinson DM; Lyseng-Williamson KA
Drugs; 2006; 66(16):2109-19; discussion 2120-1. PubMed ID: 17112304
[TBL] [Abstract][Full Text] [Related]
39. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity.
Leite CE; Mocelin CA; Petersen GO; Leal MB; Thiesen FV
Pharmacol Rep; 2009; 61(2):217-24. PubMed ID: 19443932
[TBL] [Abstract][Full Text] [Related]
40. Pleiotropic effects of rimonabant: clinical implications.
Després JP
Curr Pharm Des; 2009; 15(5):553-70. PubMed ID: 19199981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]